Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Much Will The Minimal Residual Disease Market Be Worth By 2029?

Over the past few years, the market size of minimal residual disease has expanded swiftly. It is projected to increase from $1.78 billion in 2024 to $2.01 billion in 2025, boasting a compound annual growth rate (CAGR) of 12.6%. The expansion during the historic period is a result of factors such as growing numbers of cancer patients, an increase in research and development investment, improved affordability in healthcare, a rise in blood cancer cases, and heightened public awareness.

In the coming years, a swift expansion is predicted for the minimal residual disease market, with a projected size of $3.19 billion in 2029, representing a compound annual growth rate (CAGR) of 12.3%. Factors contributing to this projected growth during the forecast period can be linked to a surge in cancer patients, the rise in government-led awareness programs, increased affordability of healthcare, a boost in disposable income within emerging economies, and initiatives from government bodies to raise cancer awareness. Predicted trends for this forecasted period encompass advancements in next-generation sequencing (NGS) technology, the standardization of MRD testing, the uptake of personalized MRD monitoring, progress in liquid biopsy technologies, and therapies targeted towards minimal residual disease.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21224&type=smp

What Market Forces Are Contributing To The Growth Of The Minimal Residual Disease Market?

The escalating occurrence of cancer is anticipated to fuel the advancement of the minimal residual disease market in the future. Characterized by uncontrolled cell growth and spread, cancer is a cluster of diseases affecting the body. This escalating occurrence can be traced back to causes such as an aging society, heightened exposure to environmental carcinogens, unhealthy living habits, and genetic susceptibilities. The upsurge in cancer prevalence amplifies the need for accurate MRD testing to identify leftover cancer cells, facilitating early countermeasures and tailored treatment. This leads to better forecasts for relapses and improved patient results. For instance, as reported by the National Cancer Institute (NCI), a US-based government body, the world saw nearly 20 million fresh cancer cases and 9.7 million cancer-related fatalities in 2022 as per the data from May 2024. The forecast for 2040 projects a staggering 29.9 million new instances and 15.3 million cancer-related deaths. Hence, the escalating occurrence of cancer is the catalyst driving the advancement of the minimal residual disease market.

Which Segments Define The Structure Of The Minimal Residual Disease Market?

The minimal residual diseasemarket covered in this report is segmented –

1) By Detection Target: Lymphoma; Leukemia; Solid Tumors; Other Detection Targets

2) By Test Technique: Flow Cytometry; Polymerase Chain Reaction (PCR); Next Generation Sequencing (NGS); Other Test Techniques

3) By End-User: Banking, Financial Services, And Insurance (BFSI); Retail And E-Commerce; Hospitals; Diagnostic Laboratories; Research Institutions

Subsegments:

1) By Lymphoma: Hodgkin Lymphoma; Non-Hodgkin Lymphoma

2) By Leukemia: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia

3) By Solid Tumors: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer

4) By Other Detection Targets: Multiple Myeloma; Neuroblastoma; Sarcomas

Which Long-Term Trends Will Play A Crucial Role In The Minimal Residual Disease Market?

Companies in the minimal residual disease (MRD) market are developing next-gen in vitro diagnostic (IVD) tests to enable precise, individualized treatment strategies. IVD tests detect leftover cancer cells after therapy, helping predict relapse. In December 2022, US-based Adaptive Biotechnologies Corporation launched the clonoSEQ Assay to identify MRD in diffuse large B-cell lymphoma (DLBCL). This blood-based test evaluates circulating tumor DNA for a sensitive and non-invasive method to detect early recurrence. It’s the first MRD test for DLBCL to gain Medicare coverage, making it widely available across treatment types.

Which Firms Are Making The Biggest Impact In The Minimal Residual Disease Market?

Major companies operating in the minimal residual disease market are Thermo Fisher Scientific Inc., Amgen Inc., Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Kite Pharma Inc., Natera Inc., Foundation Medicine Inc., NeoGenomics Inc., Guardant Health Inc., Grail LLC, Tempus AI Inc., Veracyte Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., Mission Bio Inc., ArcherDx Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/minimal-residual-disease-global-market-report

Which Region Is Forecasted To Lead The Minimal Residual Disease Market In The Coming Years?

North America was the largest region in the minimal residual disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minimal residual disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21224&type=smp

Browse Through More Reports Similar to the Global Minimal Residual Disease Market 2025, By The Business Research Company

Inflammatory Bowel Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Chronic Disease Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report

Liver Diseases Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model